New co-authored paper on changes in clinical parameters of new T2D users of oral semaglutide in the Netherlands using the PHARMO Data Network.
In this new paper, the PHARMO Institute conducted a retrospective cohort study using the PHARMO Data Network evaluate clinically relevant endpoints in type 2 diabetes (T2D) patients initiating oral semaglutide in the netherlands. Patients who initiated oral semaglutide experienced significantly reductions in HbA1c and body weight over the course of the study, in line with the clinical trial data, providing evidence of consistent beneficial changes in clinical measurements during treatment with oral semaglutide in a real-world setting.
The study highlights the need for tailored approaches to address barriers in glycaemic control, including potential differences in treatment intensification, lifestyle support, and patient–provider communication.
Read the paper, available open access via Diabetes, Obesity, and Metabolism:
